| Product Code: ETC7345347 | Publication Date: Sep 2024 | Updated Date: Sep 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Greece Clinical Oncology NGS Market Overview |
3.1 Greece Country Macro Economic Indicators |
3.2 Greece Clinical Oncology NGS Market Revenues & Volume, 2021 & 2031F |
3.3 Greece Clinical Oncology NGS Market - Industry Life Cycle |
3.4 Greece Clinical Oncology NGS Market - Porter's Five Forces |
3.5 Greece Clinical Oncology NGS Market Revenues & Volume Share, By Technology, 2021 & 2031F |
3.6 Greece Clinical Oncology NGS Market Revenues & Volume Share, By Workflow, 2021 & 2031F |
3.7 Greece Clinical Oncology NGS Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.8 Greece Clinical Oncology NGS Market Revenues & Volume Share, By End-use, 2021 & 2031F |
4 Greece Clinical Oncology NGS Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of cancer in Greece |
4.2.2 Growing adoption of Next-Generation Sequencing (NGS) technology in clinical oncology |
4.2.3 Government initiatives to improve healthcare infrastructure and access to advanced technologies |
4.3 Market Restraints |
4.3.1 High cost associated with NGS technology implementation |
4.3.2 Lack of skilled professionals in clinical oncology and genomics in Greece |
5 Greece Clinical Oncology NGS Market Trends |
6 Greece Clinical Oncology NGS Market, By Types |
6.1 Greece Clinical Oncology NGS Market, By Technology |
6.1.1 Overview and Analysis |
6.1.2 Greece Clinical Oncology NGS Market Revenues & Volume, By Technology, 2021- 2031F |
6.1.3 Greece Clinical Oncology NGS Market Revenues & Volume, By Whole Genome Sequencing, 2021- 2031F |
6.1.4 Greece Clinical Oncology NGS Market Revenues & Volume, By Whole Exome Sequencing, 2021- 2031F |
6.1.5 Greece Clinical Oncology NGS Market Revenues & Volume, By Targeted Sequencing & Resequencing Centrifuges, 2021- 2031F |
6.2 Greece Clinical Oncology NGS Market, By Workflow |
6.2.1 Overview and Analysis |
6.2.2 Greece Clinical Oncology NGS Market Revenues & Volume, By Pre-Sequencing, 2021- 2031F |
6.2.3 Greece Clinical Oncology NGS Market Revenues & Volume, By Sequencing, 2021- 2031F |
6.2.4 Greece Clinical Oncology NGS Market Revenues & Volume, By Data Analysis, 2021- 2031F |
6.3 Greece Clinical Oncology NGS Market, By Application |
6.3.1 Overview and Analysis |
6.3.2 Greece Clinical Oncology NGS Market Revenues & Volume, By Screening, 2021- 2031F |
6.3.3 Greece Clinical Oncology NGS Market Revenues & Volume, By Companion Diagnostics, 2021- 2031F |
6.3.4 Greece Clinical Oncology NGS Market Revenues & Volume, By Other Diagnostics, 2021- 2031F |
6.4 Greece Clinical Oncology NGS Market, By End-use |
6.4.1 Overview and Analysis |
6.4.2 Greece Clinical Oncology NGS Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 Greece Clinical Oncology NGS Market Revenues & Volume, By Clinics, 2021- 2031F |
6.4.4 Greece Clinical Oncology NGS Market Revenues & Volume, By Laboratories, 2021- 2031F |
7 Greece Clinical Oncology NGS Market Import-Export Trade Statistics |
7.1 Greece Clinical Oncology NGS Market Export to Major Countries |
7.2 Greece Clinical Oncology NGS Market Imports from Major Countries |
8 Greece Clinical Oncology NGS Market Key Performance Indicators |
8.1 Percentage increase in the number of NGS tests conducted in clinical oncology settings in Greece |
8.2 Average turnaround time for NGS test results in clinical oncology |
8.3 Rate of adoption of NGS technology by oncologists and healthcare facilities in Greece |
9 Greece Clinical Oncology NGS Market - Opportunity Assessment |
9.1 Greece Clinical Oncology NGS Market Opportunity Assessment, By Technology, 2021 & 2031F |
9.2 Greece Clinical Oncology NGS Market Opportunity Assessment, By Workflow, 2021 & 2031F |
9.3 Greece Clinical Oncology NGS Market Opportunity Assessment, By Application, 2021 & 2031F |
9.4 Greece Clinical Oncology NGS Market Opportunity Assessment, By End-use, 2021 & 2031F |
10 Greece Clinical Oncology NGS Market - Competitive Landscape |
10.1 Greece Clinical Oncology NGS Market Revenue Share, By Companies, 2024 |
10.2 Greece Clinical Oncology NGS Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here